Target
FGFR3
21 products, 25 indications
Indications
hepatocellular carcinoma (3 products)
Stage III melanoma (3 products)
NSCLC (2 products)
recurrent endometrial cancer or ovarian cancer (2 products)
metastatic non-small cell lung cancer (2 products)
Advanced melanoma (2 products)
advanced hepatocellular carcinoma (2 products)
NSCLC with EGFR mutations and ALK rearrangements with brain metastases (1 products)
advanced-stage, anti-PD1/PD-L1 relapsed/refractory solid tumors (1 products)
Small cell prostate cancer (SCPC) and treatment-emergent neuroendocrine prostate cancer (tNEPC) (1 products)
Advanced Endometrial Cancer (1 products)
mucosal melanoma (1 products)
stage III/IV unresectable melanoma (1 products)
Locally Advanced Gastric Cancer (1 products)
metastatic melanoma (1 products)
advanced and refractory melanoma (1 products)
Platinum-sensitive recurrent ovarian carcinoma (1 products)
High-grade serous ovarian cancer (HGSOC) (1 products)
Borderline-resectable hepatocellular carcinoma (1 products)
Platinum-resistant recurrent ovarian carcinoma (1 products)
Advanced non-small cell lung cancer with actionable driver oncogenes (1 products)
Unresectable hepatocellular carcinoma (1 products)
malignant mesothelioma (1 products)
advanced adenocarcinoma of the lung (1 products)
FGFR+ Muscle Invasive Bladder Cancer (1 products)
Loading...
3 drugs
60 abstracts
Abstract
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Memorial Sloan Kettering Cancer Center, FLENI,
Abstract
Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.Org: Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, Tohoku University Hospital, Miyagi, Japan, National Center for Global Health and Medicine, Tokyo, Japan, NHO Shikoku Cancer Center, Ehime, Japan, Showa University, Tokyo, Japan,
Abstract
Efficacy and safety of erdafitinib in adults with breast cancer and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.Org: Hospital Privado de la Comunidad de Mar del Plata, Buenos Aires, Argentina, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Vall d’Hebron Barcelona Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain, Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France, Department of Oncology, AK Altona, Asklepios Tumourzentrum Hamburg, Hamburg, Germany,
Abstract
First-in-human study of simmitinib, a novel tyrosine kinase inhibitor targeting FGFR1-3, KDR and CSF-1R.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, Chongqing University Cancer Hospital, Chongqing, China, Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Henan Cancer Hospital, Zhengzhou, China, Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China, Fujian Provincial Cancer Hospital, Fuzhou, China, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Yunnan Cancer Hospital, Yunnan, China, First Affiliated Hospital Of Gannan Medical University, Ganzhou, China, CSPC Pharmaceutical Group Limited, Shijiazhuang, China, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
RNA expression-based hypoxia score as a prognostic and predictive biomarker in hepatocellular carcinoma.Org: JC Walter Jr Center for Transplantation and Sherrie and Alan Conover Center for Liver Disease and Transplantation,
Abstract
FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).Org: Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Greenberg Bladder Cancer Institute,
Abstract
The efficacy and safety of toripalimab combined with anlotinib in the first-line treatment of Chinese patients with metastatic melanoma.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,
Abstract
SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.Org: University of Sheffield, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy Département d'Organisation du Parcours Patient, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.Org: Kaiser Permanente San Diego, Kaiser Permanente National Drug Use Management,
Abstract
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,
Abstract
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).Org: Liver Cancer Institute, Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Department of Hepatic Surgery V, Center of Hepato-Pancreato-Biliary Surgery,
Abstract
Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.Org: The People's Liberation Army 81 Hospital, University Hospital Gasthuisberg, Bristol Haematology and Oncology Centre, Statistics & Decision Sciences, Janssen China R&D Center, Chi-Mei Medical Center,
Abstract
Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.Org: University of Miami Hospital and Clinics, Cancer Research Services, New York Oncology Hematology, Moscow City Clinical Oncology Hospital No. 1, Alexandra General Hospital,
Abstract
FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study.Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Medicine, Division of Hematology/Oncology, University of Washington, Fred Hutchinson Cancer Center, Department of Pathology, SUNY Upstate Medical University,
Abstract
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.Org: Weill Medical College at Cornell University,
Abstract
Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from the HCC CHORD database.Org: Halifax, NS, Canada, Winnipeg, MB, Canada,
Abstract
Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
FGF19-FGFR4 axis as the inaugural target for determining the efficacy of advanced esophageal cancer treatment.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Nanfang Hospital, Southern Medical University,
Abstract
Kinome reprogramming as a therapeutic opportunity in ESR1 fusion driven breast cancer but not in gynecologic cancers.Org: Caris Life Sciences Research and Development, Tempero Bio, Azidus Brasil, Caris Life Sciences, Phoenix Tissue Repair,
Abstract
CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,
Abstract
Efficacy and safety of regorafenib plus ICIs as second-line treatment in advanced HCC post-frontline treatment failure: A real-world study from a single center.Org: PLA General Hospital,
Abstract
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.Org: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Privado de la Comunidad de Mar del Plata, Buenos Aires, Argentina, Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study.Org: Department of General Surgery (Hepatopancreatobiliary Surgery), Affiliated Hospital of Southwest Medical University, Luzhou, The Affiliated Hospital of Southwest Medical University, Luzhou,
Abstract
Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study).Org: First People’s Hospital of Foshan, Foshan First People's Hospital,
Abstract
Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis.Org: the Naval Medical University,
Abstract
Integrative genomic analysis examines molecular and clinical disparities between bladder urothelial carcinoma and upper tract urothelial carcinoma.Org: Konyang University Hospital,
Abstract
Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).Org: Weill Cornell Medicine, New York, NY, MD Anderson Cancer Center, Houston, TX, National Cancer Institute, Rockville, MD, Children's Oncology Group, Monrovia, CA, Texas Children's Cancer and Hematology Center, Houston, TX,
Abstract
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).Org: Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan, Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Medical Oncology Department, Institut de Cancérologie du Gard - CHU Caremeau, Nimes, France, Department of Medical Oncology, Centre Eugene Marquis, Rennes, France, Seoul National University Hospital, Seoul, Korea, Republic of (South),
Abstract
Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository.Org: Memorial Sloan Kettering Cancer Center,
Abstract
An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).Org: Memorial Sloan Kettering Cancer Center,
Abstract
Genomic alterations and self-reported Agent Orange exposure in United States veterans with metastatic prostate cancer.Org: David Geffen School of Medicine at University of California Los Angeles (UCLA), Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Veterans Affairs Greater Los Angeles Healthcare System, VA National Oncology Program and Durham VA Medical Center, University of Pennsylvania,
Abstract
A phase 0 pharmacokinetic trigger trial of infigratinib in patients with recurrent high-grade glioma.Org: Ivy Brain Tumor Center, Barrow Neurological Institute,
Abstract
ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations.Org: Kinnate Biopharma, Guardant Health, Inc.,
Abstract
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, Foundation Medicine, Inc., Cambridge, MA, Vanderbilt University Medical Center,
Abstract
Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.Org: Department of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC, Canada, Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, Department of Medical Oncology, BC Cancer-Victoria Centre, Victoria, BC, Canada, Department of Medical Oncology, BC Cancer-Surrey Centre, Surrey, BC, Canada, Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada,
Abstract
Accuracy of genome-wide mutational analysis for tumor-informed ctDNA-guided MRD monitoring in bladder cancer.Org: Aarhus University Hospital, C2i Genomics Inc., C2i Genomics Ltd.,
Abstract
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.Org: Janssen Research & Development, Beerse, PA, Belgium, Janssen Research & Development, Shanghai City, China, Janssen Research & Development, Spring House, PA,
Abstract
A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer.Org: Massachusetts Eye and Ear Infirmary, Harvard Medical School, Northshore University Healthsystem, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Frequency and spectrum of clinically significant molecular alterations detected by tumor gene panel testing for pediatric cancer patients in the Texas KidsCanSeq study.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Invitae, Nationwide Children’s Hospital, Phoenix Children's Hospital,
Abstract
Investigating alterations in cancer driver genes and other potentially targetable mutations in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial.Org: UCL-University College London (United Kingdom ), University of Edinburgh Cancer Research UK Centre, Institute of Cancer & Genomic Sciences, University of Birmingham, University of Southampton NHS Foundation Trust, Bill Lyons Informatics Centre, London,
Abstract
Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).Org: Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH,
Abstract
Clinical utility of plasma ctDNA sequencing in metastatic urothelial carcinoma.Org: Institut Gustave Roussy, Gustave Roussy and Paris Saclay University, Villejuif, France, Gustave Roussy Département d'Organisation du Parcours Patient, Département Interdisciplinaire D’organisation Du Parcours Patient (DIOPP), Department of Medical Biology and Pathology, Gustave Roussy, France, Paris,
Abstract
A phase 1b study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.Org: National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa-Shi, Japan Association for Development of Community Medicine, Graduate School of Medicine Chiba University, Chiba, Japan,
Abstract
CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).Org: H. Lee Moffitt Cancer Center and Research Institute, Vita-Salute San Raffaele University, Saint Louis University Hospital, University of Washington; Fred Hutchinson Cancer Center, SUNY Upstate Medical University,
Abstract
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.Org: Sutter/California Pacific Medical Center, Marqués de Valdecilla University Hospital, IDIVAL, The Chinese University of Hong Kong, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”,
Abstract
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,
Abstract
Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study.Org: The Second Affiliated Hospital of Air Force Medical University, Xi'an Medical College,
Abstract
A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.Org: HUTCHMED Limited, Shanghai, China,
Abstract
Use of an artificial intelligence (AI) –based pre-screening tool for patients with bladder cancer with fibroblast growth factor receptor (FGFR) alteration.Org: Shanghai OrigiMed Co., Ltd., Shanghai, China, Fifth Affiliated Hospital of Sun-yet Sen University,
Abstract
TIPS combined with lenvatinib and PD-1 inhibitor in patients with advanced HCC with symptomatic portal hypertension: A retrospective study.Org: Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Clinical outcomes in patients with radioiodine refractory thyroid carcinoma treated with dose-reduced lenvatinib.Org: Rush University Medical Center,
Abstract
Landscape of FGFR2/3 alterations in hepatobiliary malignancies.Org: Nanfang Hospital, Southern Medical University, Guangzhou, China, AcornMed Biotechnology Co., Ltd., Beijing, China, Beijing, China,
Abstract
Biliary intervention combined with lenvatinib+ PD-1 inhibitor of Klatskin tumor complicated with malignant obstructive jaundice.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study.Org: Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Performance of the OncoUrine test on the predictive capacity of non-muscle-invasive bladder cancer patients who are candidates for repeated transurethral resection.Org: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Jichenjunchuang Medical Laboratory(Hangzhou), Co. Ltd., Hangzhou, China, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
Abstract
Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study.Org: The Second Affiliated Hospital Of Nanchang University, Nanchang, China National Biotec Group,
Abstract
Landscape of FGFR2/3 alterations in genitourinary cancer.Org: First Affiliated Hospital of Dalian Medical University, AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
Efficacy and safety of transarterial chemoembolization in combination with lenvatinib and tislelizumab for patients with unresectable BCLC-B stage hepatocellular carcinoma classified as beyond up to seven criteria: A retrospective study.Org: Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center and Sun Yat-sen University State Key Laboratory of Oncology in South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,
Abstract
Real world genomics in metastatic urothelial carcinoma (mUC).Org: University Hospitals Seidman Cancer Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Department of Medical Genetics, Cleveland, OH, Cancer Informatics,
Drug
LenvatinibDrug
NintedanibAbstract
The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer.Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Cincinnati Medical Center, Brown University - Lifespan Cancer Institute, Hoag Family Cancer Institute and University of Southern California,
Drug
Erdafitinib